Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Moodys
McKinsey
Harvard Business School
Johnson and Johnson

Last Updated: September 26, 2022

REYVOW Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Reyvow patents expire, and what generic alternatives are available?

Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-eight patent family members in forty-two countries.

The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.

DrugPatentWatch® Generic Entry Outlook for Reyvow

Reyvow will be eligible for patent challenges on January 31, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for REYVOW
International Patents:78
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 63
Patent Applications: 104
Drug Prices: Drug price information for REYVOW
What excipients (inactive ingredients) are in REYVOW?REYVOW excipients list
DailyMed Link:REYVOW at DailyMed
Drug patent expirations by year for REYVOW
Drug Prices for REYVOW

See drug prices for REYVOW

DrugPatentWatch® Estimated Generic Entry Opportunity Date for REYVOW
Generic Entry Date for REYVOW*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for REYVOW

US Patents and Regulatory Information for REYVOW

REYVOW is protected by three US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of REYVOW is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting REYVOW

Compositions and methods related to pyridinoylpiperidine 5-HT.sub.1F agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Pyridinoylpiperidines as 5-HT.sub.1F agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Pyridinoylpiperidines as 5-HT.sub.1F agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

FDA Regulatory Exclusivity protecting REYVOW

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for REYVOW

When does loss-of-exclusivity occur for REYVOW?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 17373784
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2019010934
Estimated Expiration: See Plans and Pricing

Canada

Patent: 43772
Estimated Expiration: See Plans and Pricing

Chile

Patent: 19001426
Estimated Expiration: See Plans and Pricing

China

Patent: 0291079
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 19005290
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 190251
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0211557
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 51617
Estimated Expiration: See Plans and Pricing

Dominican Republic

Patent: 019000139
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 19040190
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 1991112
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 51617
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 56820
Estimated Expiration: See Plans and Pricing

Israel

Patent: 6598
Estimated Expiration: See Plans and Pricing

Japan

Patent: 20500936
Estimated Expiration: See Plans and Pricing

Patent: 22000451
Estimated Expiration: See Plans and Pricing

Jordan

Patent: 0190129
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 51617
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 19006520
Estimated Expiration: See Plans and Pricing

Moldova, Republic of

Patent: 51617
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 920
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 2906
Estimated Expiration: See Plans and Pricing

Peru

Patent: 191134
Estimated Expiration: See Plans and Pricing

Philippines

Patent: 019501252
Estimated Expiration: See Plans and Pricing

Poland

Patent: 51617
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 51617
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 415
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 51617
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1903449
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 190075130
Estimated Expiration: See Plans and Pricing

Patent: 210102497
Estimated Expiration: See Plans and Pricing

Spain

Patent: 89476
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 71290
Estimated Expiration: See Plans and Pricing

Patent: 1833097
Estimated Expiration: See Plans and Pricing

Tunisia

Patent: 19000174
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 4433
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REYVOW around the world.

Country Patent Number Title Estimated Expiration
Chile 2019001426 Composiciones y m├ętodos relacionados con agonistas de piridinoilpiperidina 5-ht1f. See Plans and Pricing
Taiwan I263497 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2018106657 See Plans and Pricing
Mexico PA04009497 PIRIDINOILPIPERIDINAS COMO ANTAGONISTAS DE 5-HT1F. (PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Moodys
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.